SCHEMBL10114394

SCHEMBL10114394

C[C@@H]1CN(S(=O)(=O)c2ccc(NC(=O)[C@H]3CC[C@H](NS(=O)(=O)C(C)(C)C)CC3)cc2)C[C@H](C)O1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DDIT3 P35638 1/20 0.48
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
NAMPT P43490 2/20 0.48
CYP2C9 P11712 1/20 0.48
USP2 O75604 2/20 0.47
NPC1 O15118 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
MAPT P10636 2/20 0.47
GAA P10253 2/20 0.47
LMNA P02545 1/20 0.47
HPGD P15428 1/20 0.47
ALOX15 P16050 1/20 0.47
MAPK1 P28482 1/20 0.47
NPY5R Q15761 1/20 0.46
POLB P06746 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
ALDH1A1 P00352 2/20 0.46
THRB P10828 1/20 0.46
RXFP1 Q9HBX9 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13204163 1.00 DDIT3 (0.48) DDIT3MEN1KMT2ANAMPTCYP2C9
SCHEMBL10133402 1.00 DDIT3 (0.48) DDIT3MEN1KMT2ANAMPTCYP2C9
SCHEMBL14418439 0.89 RXFP1 (0.49) USP2TDP1MAPTGAALMNA
SCHEMBL10134442 0.89 RXFP1 (0.49) USP2TDP1MAPTGAALMNA
SCHEMBL14424260 0.89 RXFP1 (0.49) USP2TDP1MAPTGAALMNA
SCHEMBL10114397 0.89 RXFP1 (0.49) USP2TDP1MAPTGAALMNA
SCHEMBL10133980 0.87 MAPT (0.50) NAMPTMAPTLMNANPY5RALDH1A1
SCHEMBL278192 0.87 MAPT (0.50) NAMPTMAPTLMNANPY5RALDH1A1
SCHEMBL10114327 0.87 MAPT (0.50) NAMPTMAPTLMNANPY5RALDH1A1
SCHEMBL13204166 0.87 MAPT (0.50) NAMPTMAPTLMNANPY5RALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8115027-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2012-02-14 US disclosed
US-20100292500-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2010-11-18 US disclosed
US-7265130-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2007-09-04 US disclosed
US-20070015762-A1 NPY Y5 antagonist KAWANISHI YASUYUKI 2007-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070015762-A1 NPY Y5 antagonist NPY5R, NPY1R, NPY2R DDIT3 4749/4885MEN1 2876/4885KMT2A 2912/4885
US-20100292500-A1 NPY Y5 ANTAGONIST NPY5R, NPY1R, NPY2R DDIT3 4672/4885MEN1 2932/4885KMT2A 2768/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.